Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.

ABSTRACT: Interventions: Cetuximab: Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1 and 8 every 3 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 80mg/m2, day1,8 Primary outcome(s): 1) Phase I study To determine the maximum tolerated dose (MTD) and recommended dose (RD) 2) Phase II study Response rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer: Kras Wild Type

PROVIDER: 2618747 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase1 trial of Panitumumab combined with S-1 and irrinotecan in advanced/metastatic colorectal cancer

Project description:Interventions: Panitumumab:Bi-weekly administration 6 mg/kg TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1,8 every 4 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 125mg/m2, day1 Primary outcome(s): Maximum tolerated dose Recommended dose Study Design: Single arm Non-randomized

| 2620191 | ecrin-mdr-crc

Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancer

Project description:Interventions: Cetuximab: Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1 every 3 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 150mg/m2, day1 Primary outcome(s): Maximum tolerated dose Recommended dose Study Design: Single arm Non-randomized

| 2619160 | ecrin-mdr-crc

Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.

Project description:Interventions: CPT-11 150mg/m2 i.v. (day1) Bev 7.5mg/kg i.v. (day1) S-1 80mg/m2 p.o. (day1-14) to be repeated every 3 weeks Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2621739 | ecrin-mdr-crc

Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer

Project description:Interventions: S-1 : day1-14 80mg/m2. CPT-11 : day1 150mg/m2 Cetuximab : day1,8,15 400mg/m2 (1st time) , 250mg/m2 (2nd time or another) to be repeated every 3 weeks Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2622216 | ecrin-mdr-crc

Phase II study of neoadjuvant chemotherapy with CPT-11 and S-1 for locally advanced colorectal cancer with lymph node metastases.

Project description:Interventions: S-1 80mg/m2/day for 14 days plus CPT-11 100mg/m2 on day 1 and 15 every 28 days is administered for 2 course. After treatment, response rate is evaluated. Surgical operation is performed. Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2617187 | ecrin-mdr-crc

Randomized phase II trial of Hange-shasin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS+Bev second-line treatment

Project description:Interventions: S-1+CPT-11+bevacizumab+Placebo S-1 80-120mg/day day1-14 q4w CPT-11 100mg/m2 day1,15 q4w Bevacizumab 5mg/kg day1, 15 q4w Placebo day1-28 q4w S-1+CPT-11+bevacizumab+hange-shashin-to S-1 80-120mg/day day1-14 q4w CPT-11 100mg/m2 day1,15 q4w Bevacizumab 5mg/kg day1, 15 q4w Hange-shashin-to 7.5g/day day1-28 q4w Primary outcome(s): Incidence of grade 3 or more diarrhea until the end of 3rd cycle Study Design: Parallel Randomized

| 2627635 | ecrin-mdr-crc

Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer -Beyond Progression Disease of capecitabine and bebacizumab -

Project description:Interventions: Bevacizumab (7.5mg/kg) and CPT-11(200mg/m2) is administered on day1, and capecitabine (1600mg/m2) is administered from day 1 to day 14 Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2622299 | ecrin-mdr-crc

A phase II Study of Useful therapeutic strategy for metastatic Colorectal Cancer to Evaluate Oxaliplatin Stop and Go in SOX+Bmab

Project description:Interventions: TS-1 80mg/m2/day (day1-14) and Oxaliplatin 130mg/m2 (day1) and Bevacizumab 7.5mg/kg (day1) every 21 days for 4 courses followed by TS-1 80mg/m2/day (day1-14) and Bevacizumab 7.5mg/kg (day1) every 21 days for 8 courses. And next, administer until PD the same SOX+Bmab regimen. Primary outcome(s): Progression-free Survival Study Design: Single arm Non-randomized

| 2622829 | ecrin-mdr-crc

Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)

Project description:Interventions: MetronomicIRIS(S-1/CPT-11)/Cmab combination therapy S-1:50 or 60 or 80mg/body/day(day3-7,10-14,17-21,24-28) CPT-11:60mg/m2(day1,8,15) Cmab*:250mg/m2(day1,8,15,22) *:400mg/m2 for the initial dosing(day1) every 4 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

| 2627425 | ecrin-mdr-crc

Phase II study of combination chemotherapy with TS-1/irinotecan and bevacizumab as second-line therapy in patient with K-RAS mutation-type metastatic colorectal cancer

Project description:Interventions: TS-1+CPT-11+Bevacizumab TS-1 : 80,100,120mg/twice/day1-14,following two weeks off CPT-11 : 100mg/m2/biweekly Bevacizumab : 5mg/kg/biweekly Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2621336 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data